MDS with low blast percentage and SF3B1 mutation (MDS-SF3B1) is a distinct 2022 WHO and ICC classification sub-category, replacing the MDS-RS of the previous WHO revision. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.